Stentys attracts experienced medical officer to work on new-generation stent
This article was originally published in Clinica
Executive Summary
Stentys, a French company focused on developing a “next-generation” drug-eluting stent, has appointed vascular device specialist René Spaargaren as chief medical officer. Dr Spaargaren joins the Paris-based company from vascular and neurovascular device maker ev3 (Minnesota) where, as vice-president of international clinical affairs, he drove product development and launches. His appointment will help to establish the usability for physicians of the firm’s coronary artery bifurcation stent (currently undergoing clinical evaluation and expected to enable patients to avoid open-chest surgery), said CEO and co-founder Gonzague Issenmann. Dr Spaargaren has held senior positions with Boston Scientific (medical director, Europe) and Medtronic’s cardiac assist venture (clinical manager, Europe).
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.